Topic

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Articles

Shutting down the COVID-19 pandemic requires a global, selfless effort.

After a difficult year, bio/pharma science delivers promising results.

Editor of Pharmaceutical Technology Europe

Transparency and open-dialogue are vital to sway the vaccine-hesitant community.

Industry wants clarification on compliance following the end of the Brexit transition period.

Resolving drug shortages starts with identifying the source of the problem.

Misleading messages contribute to eroding trust in public health agencies.

European pharma companies may have a vested interest in the outcome of the US elections.

AstraZeneca has potentially taken poll position in the race to develop a novel coronavirus vaccine, but will AZD1222 be ready in 2020?

Amid high expectations for a vaccine, bio/pharma readies capacity, weighs pressures.

Time sure flies, except when you are waiting for something to happen. 